anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Artificial intelligence (AI) has garnered tremendous attention in health care, and many hope that AI can enhance our health system's ability to care for people with chronic and degenerative conditions, including Parkinson's Disease (PD). This paper reports the themes and lessons derived from a qualitative study with people living with PD, family caregivers, and health care providers regarding the ethical dimensions of using AI to monitor, assess, and predict PD symptoms and progression. Thematic analysis identified ethical concerns at four intersecting levels: personal, interpersonal, professional/institutional, and societal levels. Reflecting on potential benefits of predictive algorithms that can continuously collect and process longitudinal data, participants expressed a desire for more timely, ongoing, and accurate information that could enhance management of day-to-day fluctuations and facilitate clinical and personal care as their disease progresses. Nonetheless, they voiced concerns about intersecting ethical questions around evolving illness identities, familial and professional care relationships, privacy, and data ownership/governance. The multi-layer analysis provides a helpful way to understand the ethics of using AI in monitoring and managing PD and other chronic/degenerative conditions.
A study was conducted to assess the efficacy of ezetimibe in the treatment of homozygous sitosterolemia. In this multicenter, double-blind, placebo-controlled, 8-week trial, 37 patients with homozygous sitosterolemia with elevated plasma sitosterol levels (>5 mg/dL) on their current therapeutic regimen (diet, bile-acid-binding resins, statins, ileal bypass surgery and/or LDL apheresis), were randomized to receive ezetimibe (n=30) or placebo (n=7). Due to decreased bioavailability of ezetimibe in patients concomitantly receiving cholestyramine [see Drug Interactions (7.4)] , ezetimibe was dosed at least 2 hours before or 4 hours after resins were administered. Excluding the one subject receiving LDL apheresis, ezetimibe significantly lowered plasma sitosterol and campesterol, by 21% and 24% from baseline, respectively. In contrast, patients who received placebo had increases in sitosterol and campesterol of 4% and 3% from baseline, respectively. For patients treated with ezetimibe, mean plasma levels of plant sterols were reduced progressively over the course of the study. The effects of reducing plasma sitosterol and campesterol on reducing the risks of cardiovascular morbidity and mortality have not been established. 

Reductions in sitosterol and campesterol were consistent between patients taking ezetimibe concomitantly with bile acid sequestrants (n=8) and patients not on concomitant bile acid sequestrant therapy (n=21).

Limitations of Use

The effect of ezetimibe on cardiovascular morbidity and mortality has not been determined.
The puerpera in the control group received only the standard nursing care given after birth. Standard nursing care contain solely breastfeeding training. The puerpera in the control group were visited before they were discharged from the hospital to obtain their contact information and to administer them the pretest. A home visit at the end of postpartum month 3 was also planned and they were administered the posttest. After collecting the posttest data, the trainings given to the women in the intervention group on nutrition, sleep, fatigue and pilates exercises were also given to the women in the control group in consideration of the ethical dimension of the study; they were actively trained on pilates exercises by the investigator and the relevant leaflets were given to them by the end of their trainings.
This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
PURPOSE: To the best of our knowledge, this is the first study conducted in Tunisia on the neurosurgical management of child cranial trauma. The objectives of the present work were to identify the causes of pediatric head injuries, explore epidemiological and clinical specificities, and analyze the short- and long-term postoperative evolution.
METHODS: A retrospective review was conducted on one hundred children with head injuries over a five-year period at one of the largest neurosurgery departments in Tunisia. The collected data encompassed demographic information, clinical presentation features, neuroimaging characteristics, surgical management, complications, and outcomes.
RESULTS: Over a five-year period, we have found 118 children who have undergone surgery, representing an annual incidence of twenty-four children per year. The average age was 10 years. Falls emerged as the primary cause of childhood head injuries in our series, followed by road traffic accidents. The most frequently encountered initial sign was the loss of consciousness (52%), followed by headaches (28%), vomiting (25%), and seizures (8%). The average time between the accident and admission to the operating unit was 10 h. Various neurosurgeries were performed, with the evacuation of an epidural hematoma being the most common procedure. At a median follow-up of 24 months, the outcomes were favorable in 88% of cases.
CONCLUSION: The main prognostic factors for head trauma in children included age, circumstances of the accident, association with polytrauma, the initial Glasgow Coma Scale, the nature of the initial cerebral lesions, and the timeliness and quality of initial management.
FIELD: medicine, stomatology. SUBSTANCE: agent has the following components: clove oil, licorice roots, gum-tree leaves, sage leaves, common balm herb, Saint-John's-wort herb, marjoram herb, tarragon herb, milfoil herb, coriander fruits, rose fruits, lemon fruits, rosemary rhizomes and roots, matricaria officinalis flowers, pot-marigold flowers, dioecious nettle leaves, celandine major herb, oak petiolate bark, pagoda-tree japonica (Sophora) fruits, coneflower purpurea herb, sea-buckthorn fruits and walnut unmatures fruits taken at the definite quantitative ratio. Agent is prepared for two stages. Plant raw is macerated with 70-% and 40-% ethyl alcohol at heated at 80-90 C for 30 min. Then obtained extracts are combined and clove oil is added to combined extract. Mixture is stirred, kept for 1 h and filtered. Agent shows the broad spectrum of biological activity: tonic, regenerative, adaptogenic properties that ensures to decrease the treatment period by 2-fold. Method provides the extraction of all complex of active substances. EFFECT: enhanced effectiveness of treatment, improved method of preparing. 3 cl, 1 ex
Impaired Liver Function

Do not use NuvaRing in women with liver disease such as acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal and CHC causation has been excluded [see Use in Specific Populations (8.6)]. Discontinue NuvaRing use if jaundice develops.

Liver Tumors

NuvaRing is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with CHC use. An estimate of the attributable risk is 3.3 cases per 100,000 CHC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long term (>8 years) CHC users. However, the attributable risk of liver cancers in CHC users is less than one case per million users.
In the virtual reality arm, patients will use a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and High Definition audio stereo.
PCT No. PCT/JP95/01125 Sec. 371 Date Dec. 2, 1996 Sec. 102(e) Date Dec. 2, 1996 PCT Filed Jun. 7, 1995 PCT Pub. No. WO95/34322 PCT Pub. Date Dec. 21, 1995The present invention aims at providing a method for preparing dermonecrotic toxin, an improved toxoid of dermonecrotic toxin produced by Bordetelia and a toxoid mixture comprising said improved toxoid of dermonecrotic toxin produced by Bordetella and a toxoid of dermonecrotic toxin produced by Pasteurella. There is provided a method for partially purifying dermonecrotic toxin which comprises bringing a dermonecrotic toxin-containing solution into contact with a chromatographic gel sulfated by direct sulfation or a chromatographic gel to which a sulfated molecule is covalently bonded to thereby make the dermonecrotic toxin adsorbed on the gel, and eluting the adsorbed dermonecrotic toxin from the gel. There is also provided a toxoid obtained from dermonecrotic toxin produced by Bordetella, said dermonecrotic toxin being prepared by the above method for partially purifying dermonecrotic toxin, and a toxoid mixture prepared by mixing said toxoid and a toxoid of dermonecrotic toxin produced by toxigenic Pasteurella, said toxoid mixture being safe and effective for preventing the atrophic rhinitis in pigs.
The t(11;14) translocation is among the most prevalent cytogenetic abnormalities in multiple myeloma (MM), distinguished by its unique features and biology that have been thoroughly explored for decades. What further sets this MM subtype apart is its oscillating prognostic significance, from initially being considered a favorable alteration to intermediate risk and potential future reclassification as favorable risk. Despite not being inherently a high-risk alteration indicative of an aggressive phenotype, it appears that t(11;14)-MM is less responsive to novel agents like proteasome inhibitors and immunomodulatory drugs which have otherwise transformed the disease's treatment landscape, perhaps partially explained by its reduced propensity for immunoglobulin production and oligosecretory nature. However, its distinct reliance on Bcl-2 has heightened its sensitivity to venetoclax. Further subclassification based on morphological and genomic characteristics could enhance our prediction models of treatment responses and enable more tailored therapeutic strategies for patients. This review aims to encapsulate the existing research evidence in this area.
Study design: This study will be randomized controlled trial 1. Participants: fifty males and females patients with functional shoulder impingement, aged from 25-40 years with BMI \<32kg/m2. Sample size calculation: The sample size is 50 patients in the 2 experimental groups based on power analysis done calculating effect size from outcomes of previous study (effect size d of 0.82 for shoulder proprioception) . Power analysis was done using G\*power software. Power set to (0.8), significance (0.05). Procedture: First, eligible patients will have the purpose of the study and the procedures fully explained. Then, patients will be asked to participate in the study. If they accepted, an informed consent form will be signed and randomly assigned in one of two groups. Afterwards Prior to starting of the study each patient will sign informed consent Patients will be assigned to two groups randomly (by closed envelope method). All subjects will be evaluated for their shoulder pain, disability level, and proprioception. All patients will be tested before and after the treatment program (12 treatment sessions, 3 sessions per week for 4 weeks) Conventional Physical therapy: a. Cross-body stretch b. Sleeper stretch. c. Prone extension with an externally rotated (thumb out) position d. Prone horizontal abduction e. PNF D2 flexion For intervention group it will take Cervical proprioceptive training Retraining joint position sense will be done with a laser pointer. The laser pointer will fixed on the highest point of the subject head with a band. In this exercise, patients sit upright on a chair and kept their head at the neutral position while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position . Temporary reproduction of dizziness is acceptable however exacerbation of neck pain or headache is not acceptable. If this occurs the exercises should be modified by decreasing the number of repetitions or altering the patient position to a more supported position. Progression of exercise set can be achieved by altering the duration, repetitions and the degree of difficulty of the task. Exercises can also be progressed by performing activities such as an eye task or cervical JPS practice while sitting on an unstable surface or while standing with the feet in an unstable base of support for example, heel toe stance, or while walking .
1,259,151. Bismuth complexes. W. J. SERFONTEIN. 3 Jan., 1969 [4 Jan., 1968], No. 607/69. Heading A5B. A method of testing and/or standardising a preparation based essentially on water-soluble complex bismuth ammonium hydroxy acid salts and a proteinaceous ingredient (e.g. bismuth ammonium citrate or tartrate cum pepsin) in respect of anti-ulcer activity comprises testing for the presence of water-soluble complexes of bismuth and proteinaceous matter as denoted by a positive result in at least one of the following tests:-(a) testing for the formation of a rapidly settling flocculated precipitate comprising said complexes on addition of a water-miscible organic solvent suitable for the precipitation of proteins to an aqueous solution of the preparation; (b) testing for the presence of two peaks which are developed when the composition is subjected to gel filtration at pH 9.0 on a saturated column of a gel filtration medium having essentially the characteristics of a cross-linked polydextran of a grade suitable for the separation of peptides and globular proteins in the molecular weight range of substantially 4000 to 150,000, and of which the first peak represents in excess of 10% by weight of the total bismuth of the preparation. The above tests may be supplemented by the following tests in which a positive result is indicative of clinical activity:-(c) testing for at least a 30% faster pressure increase in an osmotic pressure test as compared with a freshly prepared standard British Pharmaceutical Codex solution of bismuth ammonium citrate brought to the same bismuth and dye concentration. (d) testing whether electrophoresis at a pH of 7.0 to 10 results in the migration towards the anode of a bismuth-containing zone at less than half the rate of the rate of migration of the most rapidly moving bismuth of a freshly prepared solution of bismuth ammonium citrate according to British Pharmaceutical Codex prescription containing pepsin and dye. (e) testing whether in the peaks defined under (b) at least 2% of the total hydroxy acid content of the composition is associated with the first peak. A suitable method of preparing an active bismuth preparation comprises subjecting a substantially inactive or weakly active solution of bismuth ammonium nitrate or tartrate cum pepsin to gel filtration, thereby to prepare a concentrate of that substance which forms a first peak at pH 9.0 on a saturated column of a gel filtration medium having essentially the characteristics of a crosslinked poly-dextran of a grade suitable for the separation of peptides and globular proteins in the molecular weight range of about 4000 to 150,000, adding said concentrate to more of the said substantially inactive or weakly active solution, adding citric or tartaric acid and ammonia to adjust the pH to between 9 and 10, briefly subjecting the mixture to UV radiation with agitation at 50-65‹C, and letting the mixture stand under quiescent conditions at normal temperature until a positive result is obtained upon testing.
Background: In Uganda, the goal of GAIN's 'Vegetables for All' project is to contribute to improving the dietary diversity of Ugandans through increased consumption of safe vegetables and greater use of vegetables in Ugandan cuisine, increasing the percentage of bottom-of-the-pyramid (BoP) consumers with more adequate diets. The 'Vegetables for All' project has components focused on generating demand for safe and fresh vegetables, improving access to safe and fresh vegetables, and improving the enabling environment to support the policy and regulatory environment within which vegetable value chains function. The project resonates with Uganda's programs and interventions for preventing diet-related non-communicable diseases (DR-NCDs). Further, few evaluations of integrated nutrition and food systems programs have been conducted globally. Therefore, an evaluation of such a program would generate insights that could inform policies and program initiatives for preventing DR-NCDs in Uganda and in other contexts.

Objective: The overall objectives of the evaluation are: 1) To assess the change in the quantity (grams) of vegetables consumed in the last 24 hours before and after GAIN's Vegetables for All Project by women and children 3-9 years in BoP households in the intervention versus control areas in the study districts; 2) To assess the effect of the Vegetables for All project on secondary outcomes in BoP households in intervention versus control areas in study districts; 3) to assess the effect of the Vegetables for All project on knowledge, attitudes, and intentions related to vegetable consumption in BoP households in the intervention versus control areas in study districts; and 4) To conduct a program impact pathway analysis that will provide information that GAIN can use to adapt their program at midline and that will help support the findings of the impact evaluation at endline.

Methods: This evaluation will use a mixed-methods quasi-experimental design in which 136 FFZs are assigned to intervention or control groups across four districts. The impacts will be assessed through cross-sectional population-based surveys of households with women 18-49 years who have a child 3-9 years in the selected FFZs at baseline and endline (N=1,360 at each time point). Vegetable vendor surveys will be conducted in all 136 sampled FFZs at baseline, midline, and endline (N=408 at each time point). Qualitative data will be collected at midline and endline. In-depth interviews (IDIs) will be conducted with vegetable value chain actors and other stakeholders (N=16 at midline and endline). Focus group discussions (FGDs) will be conducted with vegetable vendors (16 FGDs at midline and endline) and household members (16 FGDs at midline and endline). The analysis will be performed using difference-in-difference estimation (surveys) and thematic content analysis methods (qualitative). A PIP analysis will be conducted at endline using a combination of qualitative and quantitative data to help understand the pathways through which the program achieved its impact.
BACKGROUND: Thomas Cullen described bleeding abnormalities and dysmenorrhea as the "expected" presentations of adenomyomas. Adenomyosis is included within the FIGO classification of structural causes of abnormal uterine bleeding (AUB). Nevertheless, this long-standing association has been questioned by some authors who reported a high incidence of adenomyosis in uteri removed for indications other than AUB or dysmenorrhea. Here, we examine evidence for the link between adenomyosis and AUB.
METHODS: A comprehensive Medline literature review of all publications to October 2023.
RESULTS: Sixty-three articles were identified and included in the review. Despite a large body of studies, the available literature does not provide conclusive evidence of a link between adenomyosis and AUB. This is because of unsuitable study design, or poor characterization of the study population or of the inclusion or exclusion criteria. Additional challenges arise because of the lack of agreed criteria for diagnosing adenomyosis and the often absence of detailed assessment of menstrual blood loss. Adenomyosis often coexists with other conditions that have also been linked to similar symptoms, and many cases of adenomyosis are asymptomatic.
CONCLUSION: Most of the existing literature and studies that addressed treatment outcome of adenomyosis started from the premise that a link between the condition and AUB had been proven. Yet, published information shows that aspects such a relationship is still uncertain. Further research is needed to address the relation between AUB and adenomyosis burden (or subtypes), distribution, and concomitant pathology.
1,134,351. Destroying microorganisms using enzymes produced by bacteria. KYOWA HAKKO KOGYO CO. Ltd. 12 April, 1967 [13 April, 1966], No. 16726/67. Heading A5E. A method for the destruction of microorganisms comprises treating the microorganisms with a cell-lytic enzyme produced from bacteria of the genus Flavobacterium. The treatment may be carried out in a solution of pH from 7.5 to 9.5, e.g. containing trishydrochloric acid or veronal hydrochloric acid. Optionally egg-white lysozyme or lysozymelike enzymes may be present. The microorganisms may be gram positive and gram negative bacteria, actinomyces, yeasts or fungi. The celllytic enzymes may be produced as described in Specification 1,132,678.
Mercury (Hg) is a ubiquitous environmental contaminant known to bioaccumulate in biota and biomagnify in food webs. Parasites occur in nearly every ecosystem and often interact in complex ways with other stressors that their hosts experience. Hepatozoon spp. are intraerythrocytic parasites common in snakes. The Florida green watersnake (Nerodia floridana) and the banded watersnake (Nerodia fasciata) occur syntopically in certain aquatic habitats in the Southeastern United States. The purpose of this study was to investigate relationships among total mercury (THg) concentrations, body size, species, habitat type and prevalence and parasitemia of Hepatozoon spp. infections in snakes. In the present study, we sampled N. floridana and N. fasciata from former nuclear cooling reservoirs and isolated wetlands of the Savannah River Site in South Carolina. We used snake tail clips to quantify THg and collected blood samples for hemoparasite counts. Our results indicate a significant, positive relationship between THg and snake body size in N. floridana and N. fasciata in both habitats. Average THg was significantly higher for N. fasciata compared to N. floridana in bays (0.22 ± 0.02 and 0.08 ± 0.006 mg/kg, respectively; p < 0.01), but not in reservoirs (0.17 ± 0.02 and 0.17 ± 0.03 mg/kg, respectively; p = 0.29). Sex did not appear to be related to THg concentration or Hepatozoon spp. infections in either species. We found no association between Hg and Hepatozoon spp. prevalence or parasitemia; however, our results suggest that species and habitat type play a role in susceptibility to Hepatozoon spp. infection.
PURPOSE: To obtain a composition which has anti-erythema activity and is capable of protecting skin from harmful effects of sunrays. CONSTITUTION: In this composition, a cosmetically-acceptable filler (e.g. in the form of an aqueous solution or emulsion) contains a 0.05 to 1 wt.% ratio or preferably 0.2 to 1 wt.% ratio of nicotinamide adenosine dinucleotide(NAD) and/or nicotinamide adenosine dinucleotide phosphate(NADP) to the total amount of the composition. It is advantageous that the NAD and/or NADP are encapsulated within small cells each having a thin film structure in an aqueous solution. At this time, each of the small cells can be partitioned from its outside with an ionic or nonionic lipid layer. The NAD and/or NADP are applied to skin before or after irradiation of the skin with sunrays, in a 10 to 20 mg/cm<2> ratio ((the weight of NAD and/or NADP)/(the skin area)).